SABCS Hot Commentary:Professor Xiaoyun Mao: A Breakthrough in “Intensified” First-Line Maintenance Therapy for HER2-Positive Metastatic Breast Cancer

SABCS Hot Commentary:Professor Xiaoyun Mao: A Breakthrough in “Intensified” First-Line Maintenance Therapy for HER2-Positive Metastatic Breast Cancer

At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), results were presented from a study titled “HER2CLIMB-05: A Randomized, Double-Blind Phase III Study of Tucatinib versus Placebo in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy for HER2-Positive Metastatic Breast Cancer” (Abstract No. GS1-01). This study explored an intensified strategy for first-line maintenance therapy in patients with HER2-positive metastatic breast cancer (HER2+ MBC). Oncology Frontier invited Professor Xiaoyun Mao from The First Hospital of China Medical University to provide a detailed overview and expert commentary on the study, with the aim of optimizing clinical decision-making.
The 17th Shanghai Breast Cancer Professional Symposium 丨Professor Benlong Yang: Exercising Caution in Surgical Indications for Advanced Breast Cancer and Strictly Upholding the Threshold for Prophylactic Mastectomy

The 17th Shanghai Breast Cancer Professional Symposium 丨Professor Benlong Yang: Exercising Caution in Surgical Indications for Advanced Breast Cancer and Strictly Upholding the Threshold for Prophylactic Mastectomy

Recently, the 17th Shanghai Breast Cancer Professional Symposium, held in conjunction with the Annual Meeting of the Breast Cancer Committee of the Shanghai Anti-Cancer Association and the 2026 Breast Cancer Guideline “Red Book” Update Meeting, took place in Shanghai. During the meeting, the 2026 Edition of the Essentials of the Breast Cancer Diagnosis and Treatment Guidelines and Specifications—jointly issued by the Chinese Anti-Cancer Association Breast Cancer Committee (CBCS) and the Breast Oncology Group of the Chinese Society of Clinical Oncology (CSOBO)—was officially released (hereinafter referred to as the new Red Book).
CASH 2026 | Prof. Wang Tianyou: Forty Years of Change in China’s Pediatric Disease Spectrum and Strategic Responses

CASH 2026 | Prof. Wang Tianyou: Forty Years of Change in China’s Pediatric Disease Spectrum and Strategic Responses

With the dawn of the new year, Tianjin once again became a hub for academic exchange. From January 9 to 11, 2026, the 6th China Annual Conference on the Development of Hematology (CASH) was grandly held in Tianjin. Bringing together leading experts in hematology from China and abroad, the conference focused on disciplinary frontiers and national health strategies, fostering in-depth discussions on the latest research advances and future directions.
ASH Global Perspectives | Prof. Wojciech Jurczak: First Results of BRUIN CLL-313 Suggest Non-Covalent BTK Inhibitors May Reshape First-Line CLL/SLL Treatment

ASH Global Perspectives | Prof. Wojciech Jurczak: First Results of BRUIN CLL-313 Suggest Non-Covalent BTK Inhibitors May Reshape First-Line CLL/SLL Treatment

Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) is a clonal proliferative disorder of mature B cells that predominantly affects older adults and is characterized by a distinctive immunophenotype. At the Late-Breaking Abstract (LBA) session of the 2025 American Society of Hematology (ASH) Annual Meeting, Professor Wojciech Jurczak from the Maria Skłodowska-Curie National Research Institute of Oncology presented the first results of the BRUIN CLL-313 study. This randomized phase III trial compared the efficacy and safety of the non-covalent BTK inhibitor pirtobrutinib with bendamustine plus rituximab (BR) in treatment-naïve patients with CLL/SLL. On-site, Oncology Frontier – Hematology Frontier invited Professor Jurczak to provide insights into the study background, design, and clinical implications, offering forward-looking guidance for clinical practice.